|| Checking for direct PDF access through Ovid
In an open-label study in India, 200 healthy participants 6–17 years of age received 13-valent pneumococcal conjugate vaccine (PCV13). PCV13 elicited robust functional antibody immune responses. No adverse events were reported by caregivers at the 1-month follow-up visit. The immunogenicity results together with the known favorable risk–benefit profile of PCV13 support extension of the indication to this age group in India.